Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the depression in Alzheimer's disease study

C. G. Lyketsos, J. M.E. Sheppard, C. D. Steele, S. Kopunek, M. Steinberg, A. S. Baker, J. Brandt, P. V. Rabins

Research output: Contribution to journalArticle

Abstract

Objective: This study evaluated the efficacy and safety of sertraline in the treatment of major depression in 22 outpatients with Alzheimer's disease. Method: Twelve of the 22 patients were given sertraline and 10 were given placebo by random group assignment for 12 weeks. Response to treatment was measured by using the Cornell Scale for Depression in Dementia. The patients were also assessed with the Hamilton Depression Rating Scale, the activities of daily living subscale of the Psychogeriatric Dependency Rating Scales, and the Mini-Mental State. Results: After 12 weeks of double-blind, placebo-controlled treatment, nine of the patients given sertraline and two of those given placebo were at least partial responders. Patients given sertraline had significantly greater mean declines from baseline in Cornell Scale for Depression in Dementia scores; the bulk of antidepressant response occurred by the third week of treatment. Conclusions: Sertraline is superior to placebo in reducing depression in patients with Alzheimer's disease who also suffer from major depression.

Original languageEnglish (US)
Pages (from-to)1686-1689
Number of pages4
JournalAmerican Journal of Psychiatry
Volume157
Issue number10
DOIs
StatePublished - Oct 21 2000

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the depression in Alzheimer's disease study'. Together they form a unique fingerprint.

  • Cite this